Unlocking New Open Internet Content Environments for Global Advertisers

HONG KONG, April 27, 2026 /PRNewswire/ — The Trade Desk (Nasdaq: TTD), a global leader in advertising technology, today announced that it has become the first-ever demand-side platform (DSP) partner for vertical short drama platform DramaBox, enabling advertisers to programmatically incorporate this fast-growing open internet content environment into their omnichannel media strategies. The partnership spans markets worldwide, helping global advertisers to achieve more efficient, measurable, and scalable audience reach in an increasingly fragmented attention landscape.

As the open internet continues to evolve, digital content formats are diversifying rapidly. Short drama, first emerging in Asia as a mobile-first content format tailored to fragmented viewing habits, has quickly gained traction worldwide. It is becoming a key part of daily online entertainment, consumed in short, intermittent viewing sessions, and complementing long-form content such as connected TV (CTV). This creates new opportunities for advertisers to build more holistic brand coverage across touchpoints with varying levels of consumer attention.

According to streaming consultancy Owl & Co., the global short drama app market is expected to generate $3 billion in revenue in 2025—nearly three times the 2024 figure—with the U.S. now the largest short drama market outside China^[1]. The analysis further shows that the top 20 apps collectively reach 250 million monthly active users^[1]. Mobile app analytics firm Sensor Tower also reports that Latin America and Southeast Asia account for roughly half of global short drama downloads^[2].

The rapid rise of short drama underscores the dynamism of the open internet and presents new opportunities for advertisers. Through this partnership with DramaBox, The Trade Desk seamlessly integrates short drama into a unified open internet programmatic framework, enabling advertisers to manage and optimize campaigns across CTV, mobile, and other premium content environments within a single platform—enhancing cross-channel consistency and efficiency.

“Short drama has become a powerful new growth engine for the global open internet digital content market,” said Wang Hefei, Head of Commercial at DramaBox. “As a leading global platform, DramaBox is committed not only to delivering high-quality short drama content to users worldwide but also to exploring sustainable monetization paths. We have chosen programmatic advertising—particularly our partnership with The Trade Desk—because of its proven global infrastructure and capabilities within the open internet ecosystem. This allows us to explore a monetization approach that is scalable, measurable, and capable of delivering real value to advertisers.”

Douglas Choy, General Manager of Inventory Development, North Asia, The Trade Desk, added, “As a new complement to the open internet, short drama—through its short duration and serialized storytelling—not only meets consumers’ fragmented viewing needs, but also provides advertisers with a high-value environment combining scale and frequency. When combined with other premium open internet content such as CTV, it further strengthens brand storytelling continuity across environments. Through this partnership with DramaBox, we look forward to helping advertisers allocate budgets more efficiently into this fast-growing content environment and unlock the full value of the open internet across channels.”

The partnership between The Trade Desk and DramaBox is now live, with advertising inventory now available to advertisers globally.

Data Sources:

1. Business Insider: These salacious, bite-sized soaps have become a $1.3 billion business in the US, Sep 2025
2. State of Short Drama Apps 2025, Sensor Tower, July 2025

About DramaBox

DramaBox is a vertical short drama entertainment platform serving global users, specializing in bite-sized, high-intensity content tailored to fragmented viewing habits. Through a hybrid content strategy combining translated adaptations and locally original productions, the platform offers a diverse range of short drama genres. Supported by multilingual interfaces and personalized recommendations, it delivers a seamless and immersive viewing experience for users across Asia, South America, North America, Africa, Europe, and Oceania.

About The Trade Desk

The Trade Desk™ is a technology company that empowers buyers of advertising. Through its self-service, cloud-based platform, ad buyers can create, manage, and optimize digital advertising campaigns across ad formats and devices. Integrations with major data, inventory, and publisher partners ensure maximum reach and decisioning capabilities, and enterprise APIs enable custom development on top of the platform. Headquartered in Ventura, CA, The Trade Desk has offices across North America, Europe and Asia Pacific. To learn more, visit thetradedesk.com or follow us on Facebook, X, LinkedIn and YouTube.

Media Contact

Supports a wide range of spectral data, including XPS, FT-IR, and NMR. From automatic determination of peak count and peak shape to background and noise estimation, AutoStatSpectra enables analysis with less dependence on individual analyst experience.

TAIPEI and SINGAPORE, April 27, 2026 /PRNewswire/ — a.s.ist Inc. (“a.s.ist”) leverages research expertise cultivated at The University of Tokyo to drive digital transformation (DX) in manufacturing through white-box AI.

a.s.ist today announced the launch of a 7-day free trial for AutoStatSpectra, its Bayesian-statistics-based spectral analysis software. During the trial period, all features will be available without restriction.

Background

In spectral analysis techniques such as XPS (X-ray Photoelectron Spectroscopy), FT-IR (Fourier Transform Infrared Spectroscopy), and NMR (Nuclear Magnetic Resonance), analytical results are heavily influenced by how overlapping peaks are separated and how the number of peaks, the parameters for each peak, and the peak function types are defined.

However, with conventional curve-fitting software, these settings often depend on the analyst’s experience and trial and error, creating challenges in objectivity and reproducibility.

AutoStatSpectra uses Bayesian inference to automatically estimate the number of peaks, peak parameters, and peak function types, while also quantifying uncertainty in the estimates. It delivers statistically grounded spectral analysis that does not rely on the analyst’s subjective judgment.

Key Features of AutoStatSpectra

1. Automatic estimation of peak count, peak parameters, and peak function types

AutoStatSpectra compares candidate models within a user-specified range and automatically selects the optimal number of peaks based on posterior probability. In addition to estimating parameters such as the height, center position, and full width at half maximum (FWHM) of each peak, it also automatically determines the most suitable peak function type for the data, including Gaussian, Lorentzian, and pseudo-Voigt functions. Because uncertainty in each estimate can also be evaluated quantitatively, the software enables highly reproducible peak fitting with less reliance on analyst experience and trial and error.

2. Flexible background correction

In addition to constant and linear background models, AutoStatSpectra supports multiple background-correction methods, including the Shirley method for XPS. Users can flexibly choose preprocessing methods according to different measurement techniques.

3. Batch analysis of multiple files (multi-file workspace)

Multiple spectral datasets can be grouped into a single workspace and processed in batch under common analysis conditions. This supports efficient analysis of large volumes of data, such as condition screening and time-series comparisons.

4. Automatic generation of analysis reports

Analysis results can be automatically output as reports in PDF and Word formats. Comprehensive reports that include fitting plots, model comparison tables, parameter lists, and posterior distribution plots significantly shorten the workflow from analysis to reporting. Data export to CSV and Excel is also supported.

5. Support for diverse data formats

AutoStatSpectra supports a wide range of data formats, including CSV, Excel, VAMAS, and SOF-H.

Demo Video

For a visual overview of how AutoStatSpectra works in practice, please watch our demo video on YouTube:
https://youtu.be/3c2pc3OJgz4 

About the Free Trial
Duration: 7 days (all features available)
Availability: Web app and desktop app
Supported environments: The desktop app supports Windows (x64) and macOS (Apple Silicon)
How to apply: Please contact us via the inquiry form on our official website: https://www.a-s-ist.com/contact/. After reviewing your target data and intended use, we will issue a trial license following a consultation. Please note that the number of trial slots is limited, and applications may close once capacity is reached.
Continuing use: After the trial period, users may continue with either a monthly plan or an annual plan.

About a.s.ist Inc.

a.s.ist is a startup that leverages advanced data analysis technologies such as white-box AI, Bayesian inference, and sparse modeling, built on research expertise cultivated at The University of Tokyo.

With strengths in data analysis for materials development, physical-property experiments, and related applications, the company supports problem-solving in research and manufacturing settings through the development and sale of automated analysis software and the provision of custom digital transformation (DX) solutions. a.s.ist is also exploring the application of emerging AI technologies such as physical AI.

Company Name: a.s.ist Inc.
CEO: Yui HAYASHI
Address: 5-17-24 Iko, Adachi-ku, Tokyo 121-0823, Japan
Founded: June 2021
URL: https://www.a-s-ist.com

SHENZHEN, China, April 27, 2026 /PRNewswire/ — The three-day WEPACK 2026 World Expo of Packaging Industry successfully concluded at Shenzhen World Exhibition & Convention Center (Bao’an), marking a milestone edition defined by record-breaking attendance, strong business outcomes, and forward-looking industry dialogue.

Organized by RX, WEPACK 2026 delivered a truly global gathering for the packaging value chain. With unprecedented scale and energy, the event showcased China’s growing integration with the global packaging industry while creating a powerful platform for international collaboration and innovation.

Record Attendance and Global Reach

Over the course of three days, WEPACK 2026 welcomed 137,157 unique visitors, representing 158,659 visits in total. Among them, 13,598 overseas visitors accounted for 19,682 visits, setting new records for both attendance and international participation.

Industry professionals from more than 130 countries and regions gathered in Shenzhen, including decision-makers, buyers, and thought leaders. Nearly 100 professional buyer delegations, comprising industry associations, alliances, and leading enterprises from around the world, conducted in-depth business exchanges across the exhibition halls—further highlighting the event’s strong commercial appeal and global influence.

A Comprehensive Showcase Across the Entire Packaging Value Chain

As a global trade platform spanning the full packaging industry chain, WEPACK 2026 brought together eight concurrent exhibitions, offering integrated solutions across key sectors: From raw paper materials and processing equipment to printing technologies and finished packaging products, the show floor presented a complete ecosystem covering corrugated packaging, folding cartons, digital printing, and label production.

Across the halls, innovation was not just displayed—it was in action. Live production lines, operating machinery, and real-time demonstrations brought solutions to life. From corrugated board and cartons to folding cartons, gift boxes, and paper bags, visitors experienced firsthand the latest advancements in automation, digitalization, and intelligent manufacturing. Meanwhile, packaging solutions across paper, plastic, metal, and glass materials showcased the diversity and creativity shaping the future of packaging.

A Hub for Industry Insights and Strategic Thinking

Beyond business and technology, WEPACK 2026 served as a platform for thought leadership. More than 30 high-level forums and concurrent events were held throughout the exhibition, including the IPIF International Packaging Innovation Forum.

Industry leaders, brand owners, packaging manufacturers, equipment suppliers, and policy experts gathered to exchange insights on key topics such as:

• Global pulp and paperboard market trends
• Sustainability and circular economy
• Digital transformation and smart manufacturing
• The future of the label industry

Each session attracted full audiences, with expert speakers delivering practical insights and strategic perspectives for decision-makers across the packaging value chain.

More Than an Exhibition: A Dynamic Industry Experience

WEPACK 2026 also redefined the traditional trade show experience. The newly launched WEPACK Carnival Zone introduced a vibrant, interactive environment designed to complement high-intensity business activities.

Featuring five themed areas—including gourmet tasting, robotics interaction, golf experience, entertainment zones, and an official merchandise store—the Carnival created a unique blend of business, culture, and leisure. This innovative approach fostered engagement, connection, and memorable experiences for global attendees.

With its record-breaking performance and comprehensive industry coverage, WEPACK 2026 has once again demonstrated its position as a leading global platform for the packaging industry. By connecting markets, technologies, and ideas, the event continues to drive the industry forward—bridging China and the world, and shaping the future of packaging together.

– 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes.

– Topline data from the Phase II study are expected in the third quarter of 2026.

HONG KONG, April 27, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today completion of enrollment in its 13-week U.S. Phase II study (NCT07321678) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). T2D is the second indication for ASC30, following its first indication of obesity. Topline data from the Phase II study for the treatment of T2D are expected in the third quarter of 2026.

“ASC30 has potential to be the best-in-class oral small molecule GLP-1 for obesity, evidenced by its efficacy and tolerability demonstrated by the U.S. Phase II study in participants with obesity or overweight,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “Expanding ASC30’s clinical development into the large diabetes treatment market is a logical next step that provides us with another chance to highlight ASC30’s potential best-in-class profile as a once-daily oral treatment option for patients. We look forward to sharing topline data from the Phase II study in diabetes participants in the third quarter of 2026.”

Dr. Wu added, “Based on the positive clinical results announced in December 2025 from our 13-week U.S. Phase II study of ASC30 in participants with obesity or overweight, the Company expects to obtain the clearance from the U.S. Food and Drug Administration and initiate Phase III trials in the U.S. for obesity indication by the end of the third quarter 2026.”

ASC30 was discovered and developed in-house at Ascletis as a first and only investigational small molecule GLP-1R fully biased agonist that can be dosed once daily orally and once monthly to once quarterly subcutaneously for the treatment of obesity, diabetes and other metabolic diseases.

About the U.S. Phase II Study with ASC30 for the Treatment of Diabetes

The Phase II study is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 tablets in participants with type 2 diabetes mellitus. The primary endpoint of the Phase II study is the mean change from baseline in HbA1c up to 13 weeks in the treatment group compared with the placebo group. Secondary endpoints include the mean change from baseline in fasting blood glucose up to 13 weeks in the treatment group compared with the placebo group, the mean change from baseline in body weight up to 13 weeks in the treatment group compared with placebo group, and safety and tolerability. The Phase II study enrolled 100 participants with type 2 diabetes mellitus at multiple sites across the U.S. Participants were randomly assigned in a ratio of approximately 2:3:3:2 to 40 mg, 60 mg and 80 mg ASC30 tablets and matching placebo tablets, respectively. ASC30 was titrated weekly from 1 mg to target doses of 40 mg, 60 mg and 80 mg.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 and ASC39, for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact:

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com 

• Signed a $348.9 million contract with the Swedish Maritime Administration for one icebreaker, to be delivered in 2029
• Won the order over leading icebreaker builders, including Finland and Norway
• “We plan to expand new export markets in the special-purpose ship sector based on our technological capabilities and integrated business expertise.”

SEOUL, South Korea, April 27, 2026 /PRNewswire/ — HD Hyundai Heavy Industries has become the first Korean shipbuilder to secure an overseas order for a dedicated icebreaker.

The company said it has signed a $348.9 million contract with the Swedish Maritime Administration to build one icebreaker.

In the bidding process, HD Hyundai Heavy Industries received strong, well-rounded evaluations for price competitiveness, delivery schedules and technological capabilities. The icebreaker under this contract is scheduled for delivery in 2029 and will provide icebreaking support, fleet operations, towing services and ice management in the Baltic Sea off Sweden.

This order was secured amid growing global attention on Arctic shipping routes and Arctic Ocean exploration, after competing with leading icebreaker builders, including Finland and Norway. It is significant as it marks the first time a South Korean shipbuilder has entered the global icebreaker market.

The deal was also the result of strong public-private cooperation, with active support from the Embassy of the Republic of Korea in Sweden and the KOTRA Stockholm Trade Office.

An icebreaker is a specialized ship designed to navigate ice-covered seas by breaking sea ice to open navigable routes. It features a reinforced hull, strong icebreaking capability and a specially designed hull form that allows it to push through and clear ice.

The icebreaker ordered by Sweden from HD Hyundai Heavy Industries will measure 126 meters in length and have a displacement of about 15,000 tons. It will feature Polar Class 4 (PC4) icebreaking capability and an electric propulsion system. PC4 generally refers to the ability to continuously break ice approximately 1 to 1.2 meters thick.

The United States has also significantly expanded its investment in icebreaker capabilities, passing legislation last year that increased related funding to about $9 billion. It has also formed the “ICE (Icebreaker Collaboration Effort) Pact” in cooperation with Canada and Finland as part of broader efforts to strengthen polar maritime operations.

According to the ICE Pact, the partners aim to build 70 to 90 icebreakers over the next 10 years.

HD Hyundai Heavy Industries aims to actively expand into the global naval and special-purpose vessel markets that require icebreaking capability, leveraging its proven expertise in building icebreakers.

“Following this icebreaker order, global recognition has been given to the strengthened business capabilities achieved through the integration of HD Hyundai Heavy Industries and HD Hyundai Mipo. We will continue to expand new export markets in the special-purpose ship segment based on our technological capabilities and integrated business expertise,” said Joo Won-ho, Head of HD Hyundai Heavy Industries’ Naval and Medium Ship Business.